CytRx Subsidary Inks Informatics Deal with 3rd Millenium
CytRx said last week that its subsidiary Araios has signed a deal to establish a computing platform for its development programs with consulting firm 3rd Millennium.
CytRx recently established Araios to use RNAi to validate small molecule drugs for Type II diabetes and obesity. (See RNAi News, 9/19/03).
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
